From early-stage discoveries to clinical validation, we provide tailored services that support every step of the journey toward effective treatments.
Our technology platforms integrate advanced stem cell biology, organoid engineering, molecular profiling, imaging-based analyses, and multi-omics to generate human-relevant disease models and translational datasets.
Whether you require a single experimental platform or a complete end-to-end pipeline, our technologies can be tailored to your research questions and therapeutic goals.
From patient samples to pluripotent stem cells
We establish patient-specific induced pluripotent stem cell (iPSC) lines from donor material, providing a renewable source of genetically relevant human cells. Together with healthy controls and genome-edited isogenic lines, these form the foundation for disease modelling and therapeutic studies.
Create precise disease models
Using CRISPR/Cas-based genome engineering, we introduce or correct disease-associated mutations, generate reporter cell lines, and create isogenic controls for mechanistic studies.
Build human tissue models
We differentiate iPSCs into highly reproducible organoids representing multiple human tissues, including brain, retina, heart, lung, skeletal muscle, and spinal cord. These models recapitulate key aspects of tissue architecture, cellular diversity, and physiological function.
Understand disease biology
We characterize organoids using advanced molecular, cellular, and functional assays to identify disease-associated phenotypes.
Discover molecular mechanisms
We combine transcriptomics, epigenomics, genomics, proteomics, and other molecular profiling approaches to reveal disease mechanisms, identify biomarkers, and uncover therapeutic targets.
Evaluate therapeutic candidates
Our organoid platforms enable testing of small molecules, biologics, gene therapies, and antisense oligonucleotides in human disease models.
Transform data into biological insight
We integrate imaging, sequencing, and functional datasets using advanced bioinformatics and AI-assisted analysis to identify disease signatures and therapeutic opportunities.